Background {#Sec1}
==========

Around 20--25% of patients with colorectal cancer (CRC) present with metastasis at initial diagnosis, while patients who are apparently cancer-free on investigation at diagnosis subsequently develop locoregional recurrence (18%), distant (78%) recurrence, or both (4%) \[[@CR1]\]. Metastasis occurs when cancer cells from the original tumor are able to proliferate in local, regional, or distant tissues; lymph nodes; or organs via lymphatic, blood, or even trans-coelomic spread \[[@CR2]\]. CRC recurrence is defined as local, regional, and distant metastatic recurrence after a disease-free period \[[@CR3]\]. Local recurrence refers to CRC relapse that occurs at the site of original surgical resection \[[@CR4]\], while regional recurrence occurs at draining lymph nodes and/or lateral pelvic lymph nodes \[[@CR3]\]. Distant metastatic recurrence involves the liver (accounts for 40--50% of metastases), the lung (accounts for 10--20% of metastases), the peritoneum, the ovaries, the adrenal glands, the bone, and the brain \[[@CR1], [@CR5]\]. It is estimated that 5-year survival rates are around 90%, 70%, and 10% for CRC localized, regional, and distant metastatic stages \[[@CR6]\].

Validating individual risk factors and even more so multivariable prediction models of multiple risk factors for local, regional, or distant metastasis and recurrence is crucially important as these could guide management of the primary tumor and provide prognostic information for patients and their cancer clinicians. Prediction models may be more successful if they consider the most informative factors. This knowledge may eventually prove useful in managing CRC treatment with better-informed patient choices. Understanding the underlying validity and predictive performance of risk factors for locoregional recurrence is particularly relevant, given progressive moves towards organ-preserving approaches such as endoscopic resection (EMR), trans-anal microscopic surgery (TEMS), and neo-adjuvant chemoradiotherapy for rectal cancer \[[@CR1]\], since organ preservation may be at the expense of elevated recurrence rates. The corollary also applies since the risk-benefit ratio of extensive locoregional surgery and/or radiotherapy may be detrimentally impacted by future distant metastases.

A number of systematic reviews (with/without meta-analyses) have investigated existing risk factors for CRC metastasis and recurrence \[[@CR7]--[@CR10]\]. However, there is a need for a comprehensive evaluation of the available epidemiological evidence. Here, we conducted an umbrella review to identify and evaluate associations between risk factors and risk of CRC metastasis and recurrence. We also systematically collected and evaluated predictive models on CRC prognostic outcomes. We then conducted a comparative cross-assessment between the identified risk factors and the predictors employed in risk prediction models to examine to what extent predictive models include the most influential factors.

Methods {#Sec2}
=======

Protocol {#Sec3}
--------

The study protocol was developed in accordance with the reporting guidance in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement \[[@CR11]\].

Umbrella review of systematic reviews (with/without meta-analyses) of risk factors {#Sec4}
----------------------------------------------------------------------------------

### Literature search and eligibility criteria {#Sec5}

A systematic search was performed in PubMed, Cochrane Library (Wiley), Web of Science (Thomson Reuters), and EMBASE (Ovid) from inception to 7 October 2019, to identify systematic reviews of observational studies with or without a meta-analysis that evaluated the associations between risk factors and risk of metastasis and recurrence in CRC (Additional file [1](#MOESM1){ref-type="media"}: Table S1). We further hand-searched reference lists of the retrieved eligible publications to identify additional relevant studies. All identified publications went through a parallel review of the title, abstract, and full text (performed by WX and YM independently) based on pre-defined inclusion and exclusion criteria following "PICOS." In particular, we included human participants from observational studies with no restriction to settings. Conversely, animal, in vitro, and in vivo experiments were excluded. For study outcomes, we included CRC metastasis (local, regional, or distant metastasis in tissues, lymph nodes, or organs at diagnosis) and CRC recurrence (local, regional, or distant metastatic recurrence in tissues, lymph nodes, or organs after a disease-free period). For study design, we included systematic reviews of observational studies with or without meta-analysis. Conversely, literature reviews, individual observational studies, systematic reviews, and meta-analyses that investigated the evidence on the efficacy of pharmaceutical drugs and therapeutic procedures were excluded. We included publications in peer-reviewed journals, and therefore, gray literature, comments, conference abstracts, and interviews were excluded.

### Data extraction {#Sec6}

Data were extracted by one investigator (WX) and checked by a second investigator (YH). For each included meta-analysis, the following items were extracted: study citation details, number of studies included, study design, study population, number of events and size of total population, risk factors, outcomes examined, reported summary meta-analytic estimates (e.g., risk ratio \[RR\], odds ratio \[OR\], hazard ratio \[HR\], the corresponding 95% confidence interval \[95% CI\], *p* value, and heterogeneity measures), instrument applied for quality and risk of bias assessment of component studies, and quality assessment result. The following items were further extracted from the individual component studies: study citation details, study design, study population, risk factors, outcomes examined, number of events and size of total population in exposed and unexposed groups, effect size, and 95% CI.

### Evidence synthesis and evaluation {#Sec7}

First, when two or more meta-analyses examining associations between the same risk factor and the same outcome were identified, the most recent meta-analysis of prospective cohort studies with the largest event number was prioritized and retained for further analysis. We also compared whether the results reported in overlapping meta-analyses were concordant in terms of direction, statistical significance, and association magnitude.

Second, we estimated the following metrics for each unique meta-analysis: (1) The summary effect size along with 95% CI was estimated based on random-effects models (DerSimonian and Laird (DL)) when the number of component studies was five or more and the Hartung-Knapp-Sidik-Jonkman (HKSJ) when the number of component studies was less than five \[[@CR12], [@CR13]\]. (2) Heterogeneity was assessed by the *I*^2^ statistic \[[@CR14]\]. (3) The 95% prediction interval was estimated. (4) The small study effect was estimated by Egger's regression asymmetry test \[[@CR15]\]. (5) Excess significance was assessed by a chi-square test \[[@CR16]\]. Based on these metrics and by applying a set of pre-defined criteria (Additional file [1](#MOESM1){ref-type="media"}: Table S8), we evaluated the credibility of the evidence for each risk factor and categorized the evidence as convincing, highly suggestive, suggestive, or weak \[[@CR17], [@CR18]\].

Lastly, for all meta-analyses that statistically represented at least 3-fold changes in the odds of the outcome, we evaluated the methodological quality and risk of bias based on the Assessment of Multiple Systematic Reviews 2.0 (AMSTAR 2.0) checklist \[[@CR19]\]. We used an odds ratio of 3.0 as a threshold for what is a substantially large effect. There is no consensus on what an optimal threshold might be, but values between 2 and 5 are proposed typically \[[@CR20]\].

### Sensitivity analysis {#Sec8}

We re-ran all meta-analyses by evaluating the outcome definitions of each individual component study reclassifying the outcomes to (i) CRC metastasis at presentation, (ii) CRC local recurrence after a disease-free period, and (iii) CRC distant recurrence after a disease-free period.

Comparative cross-assessment of risk factors and risk prediction models {#Sec9}
-----------------------------------------------------------------------

We performed a comparative cross-assessment between risk factors evaluated in the umbrella review and risk predictors included in existing prediction models. A recently published systematic review conducted by our team \[[@CR21]\] investigated a total number of 15 prediction models for prediction of metastasis and recurrence in CRC patients with surgical resection (metastasis: *N* = 6; recurrence: *N* = 9). We updated the original search to identify studies developing and/or validating risk prediction models to predict metastasis and recurrence in all CRCs, with no restriction on whether the tumor was resected. We performed a systematic search in PubMed from inception to 7 October 2019 to identify eligible studies. We extracted data relevant to study design, study population, prediction outcome, prediction time horizon, predictors, model performance, and model presentation from each included study. We created a catalog of all variables that had been included across CRC metastasis prognostic models and separately across CRC recurrence prognostic models (presented in the same order as in the respective tables). We then assessed whether the included risk predictors were evaluated or not in the umbrella review described above. If yes, we also recorded the magnitude of the summary relative risk (typically odds ratio) and noted how many of those represented at least 3-fold changes in the odds of the outcome and how many had convincing or highly suggestive evidence in our assessment.

All statistical analyses were conducted in Stata, version 14.0 (StataCorp), and R, version 3.3.0 (R Foundation for Statistical Computing).

Results {#Sec10}
=======

Literature review {#Sec11}
-----------------

A total of 2033 publications were retrieved from the systematic search in four databases. Eventually, 43 publications met all inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}: Table S2) and that included 9 systematic reviews (metastasis: *N* = 7; recurrence: *N* = 2) and 81 meta-analyses (metastasis: *N* = 61; recurrence: *N* = 20; Additional file [1](#MOESM1){ref-type="media"}: Table S3 and Table S4) of observational studies. A total of 18 overlapping meta-analyses that examined associations between the same risk factor and the same outcome were identified (Additional file [1](#MOESM1){ref-type="media"}: Table S5). The most recent meta-analysis with the largest event number was prioritized. Within the remaining 63 unique meta-analyses, 12 meta-analyses from four publications did not report detailed OR, RR, or HR in forest plots. Finally, 51 unique meta-analyses were retained for analysis, which reported 34 unique risk factors for CRC metastasis and 17 risk factors for recurrence (Additional file [1](#MOESM1){ref-type="media"}: Table S6 and Table S7). Fig. 1Flow chart summarizing the study identification and selection

Meta-analyses of risk factors for CRC metastasis {#Sec12}
------------------------------------------------

Overall, 61 eligible meta-analyses of observational studies investigating risk factors for CRC metastasis were identified (Additional file [1](#MOESM1){ref-type="media"}: Table S3). More than one meta-analysis was conducted for seven risk factors (Additional file [1](#MOESM1){ref-type="media"}: Table S5). The direction of the summary effect size and the presence of nominal statistical significance (*p* \< 0.05) of the reported associations in overlapping meta-analyses were concordant for six (86%) risk factors (Additional file [1](#MOESM1){ref-type="media"}: Table S5).

A total of 34 unique meta-analyses with available data were retained for further analysis (Additional file [1](#MOESM1){ref-type="media"}: Table S6). The median number of included component studies was five (range 2--41), the median number of the total population was 983 (range 76--10,128), and the median number of events was 138 (range 16--1808). The meta-analyses reported a wide range of risk factors (Additional file [1](#MOESM1){ref-type="media"}: Table S6): 17 histopathological risk factors (50%), 13 biomarkers (38%), three genetic risk factors (9%), and one demographic risk factor (3%). Overall, 21 (62%) of 34 unique meta-analyses reported effect sizes at *p* \< 0.05 (Table [1](#Tab1){ref-type="table"}). Based on the pre-defined credibility criteria, only one (3%) histopathological risk factor (*vascular invasion for LNM in pT1 CRC*) presented convincing evidence (see Additional file [1](#MOESM1){ref-type="media"}: Table S9 for the credibility assessment of all identified risk factors). Furthermore, 12 of 21 probed risk factors with *p* \< 0.05 had an effect size suggesting ≥ 3-fold change in the odds of the outcome, while this was also seen for the point estimates in four of 13 probed risk factors where the meta-analysis had *p* ≥ 0.05 (Table [1](#Tab1){ref-type="table"}). Table 1Summary of evidence credibility assessment of 34 unique meta-analyses of observational studies investigating the associations between risk factors and CRC metastasisPopulationOutcomeRisk factorRisk factor prevalenceEffect size (95% CI)Evidence classification**Histopathological risk factor** pT1 CRCLymph node metastasis in pT1 CRCVascular invasion330/1731 = 19%2.73 (1.98--3.78)Convincing pT1 CRCLymph node metastasis in pT1 CRCLymphatic invasion906/3347 = 27%6.78 (5.29--8.69)Highly suggestive pT1 CRCLymph node metastasis in pT1 CRCTumor budding2401/10,128 = 24%6.39 (5.23--7.80)Highly suggestive CRCLymph node metastasis in CRCTumor budding1955/6739 = 29%4.96 (3.97--6.19)Highly suggestive Rectal cancerLymph node metastasis in rectal cancerTumor size \> 1 cm203/348 = 58%6.76 (3.25--14.04)Highly suggestive pT1 CRCLymph node metastasis in pT1 CRCLymphovascular invasion340/1695 = 20%4.81 (3.14--7.36)Suggestive pT1 CRCLymph node metastasis in pT1 CRC patients who underwent additional surgeries after an endoscopic resectionLymphovascular invasion91/313 = 29%5.29 (2.34--11.98)Suggestive pT1 CRCLymph node metastasis in pT1 CRCPoor differentiation94/2722 = 4%5.61 (2.90--10.83)Suggestive Rectal cancerLymph node metastasis in rectal cancerMuscularis properia invasion122/322 = 38%5.08 (2.32--11.11)Suggestive pT1 CRCLymph node metastasis in pT1 CRCSubmucosal invasion ≥ 1 mm2389/2922 = 82%2.95 (1.39--6.27)Weak Small rectal NETsLymph node metastasis in small rectal NETs treated by local excisionLymphovascular invasion104/517 = 20%5.02 (1.16--21.72)Weak Rectal cancerLymph node metastasis in rectal cancerCentral depression32/76 = 42%3.00 (2.10--4.28)Weak Rectal cancerSynchronous metastasis in rectal cancerMRI-detected extramural vascular invasion (mrEMVI)212/804 = 26%5.65 (2.12--15.05)Weak Small rectal NETsLymph node metastasis in small rectal NETs treated by local excisionLymphatic invasion73/493 = 15%5.54 (0.02--1752.46)No association Rectal cancerLymph node metastasis in rectal cancerVascular invasion46/168 = 27%5.86 (0.77--44.62)No association Small rectal NETsLymph node metastasis in small rectal NETs treated by local excisionVascular invasion75/211 = 36%3.63 (0.05--268.57)No association pT1 CRCLymph node metastasis in pT1 CRC patients who underwent additional surgeries after an endoscopic resectionPoor or moderate differentiation122/209 = 58%3.77 (1.12--123.16)No association**Biomarker** CRCLymph node metastasis in CRCDownregulated E-cadherin expression829/1573 = 53%0.49 (0.34--0.72)Highly suggestive CRCHepatic metastasis (distant) in CRCCirculating tumor cells103/310 = 33%6.38 (2.67--15.26)Suggestive CRCLymph node metastasis in CRCLow MUC2 expression level613/1335 = 46%1.42 (1.19--1.69)Suggestive CRCDistant metastasis in CRCDownregulated E-cadherin expression509/1027 = 50%0.45 (0.23--0.91)Weak CRCLymph node metastasis in CRCCirculating tumor cells797/1802 = 44%1.62 (1.17--2.23)Weak CRCLymph node metastasis in CRCp16 protein expression482/800 = 60%0.50 (0.30--0.84)Weak CRCDistant metastasis in CRCCyclin D1 overexpression952/1515 = 63%0.60 (0.36--0.99)Weak CRCDistant metastasis in CRCβ-catenin overexpression in the nucleus283/531 = 53%0.48 (0.29--0.79)Weak CRCLymph node metastasis in CRCCD147 expression603/815 = 74%1.41 (0.39--5.01)No association CRCDistant metastasis in CRCCD147 expression405/538 = 75%2.32 (1.34E−06 to 4.03E+06)No association CRCLymph node metastasis in CRCCD133 expression550/1629 = 34%1.15 (0.82--1.62)No association CRCDistant metastasis in CRCCD133 expression300/1064 = 28%1.54 (0.39--6.09)No association CRCLymph node metastasis in CRCHER-2 immunohistochemical expression440/1289 = 34%1.90 (0.90--4.02)No association**Genetic risk factor** CRCLymph node metastasis in CRCBRAF mutation736/1142 = 64%0.75 (0.49--1.14)No association CRCLymph node metastasis in CRCRASSF1A promoter methylation100/184 = 54%1.61 (0.16--16.16)No association CRCDistant metastasis in CRCRASSF1A promoter methylation153/417 = 37%2.57 (0.64--10.24)No association**Demographic risk factor** pT1 CRCLymph node metastasis in pT1 CRCFemale gender465/1329 = 35%2.23 (0.78--6.42)No association*Abbreviation*: *CI* confidence interval, *CRC* colorectal cancer, *NET* neuroendocrine tumor

Meta-analyses of risk factors for CRC recurrence {#Sec13}
------------------------------------------------

Overall, 20 eligible meta-analyses of observational studies investigating risk factors for CRC recurrence were identified (Additional file [1](#MOESM1){ref-type="media"}: Table S4). More than one meta-analysis was conducted for three risk factors (Additional file [1](#MOESM1){ref-type="media"}: Table S5). The direction of the summary effect size and the presence of nominal statistical significance (*p* \< 0.05) of the reported associations between the same risk factor and the same outcome in overlapping meta-analyses were concordant for two (67%) risk factors (Additional file [1](#MOESM1){ref-type="media"}: Table S5).

A total of 17 unique meta-analyses with available data were retained for further analysis (Additional file [1](#MOESM1){ref-type="media"}: Table S7). The median number of included component studies was six (range 2--26), the median number of the total population was 2773 (range 252--39,745), and the median number of events was 551 (range 57--3675). The meta-analyses reported a wide range of risk factors (Additional file [1](#MOESM1){ref-type="media"}: Table S7): five histopathological risk factors (29%), two biomarkers (12%), one genetic risk factor (6%), five clinical risk factors (29%), one comorbidity (6%), and three anthropometric indices (18%). Overall, 11 (65%) of 17 unique meta-analyses reported effect sizes at *p* \< 0.05 (Table [2](#Tab2){ref-type="table"}). Table 2Summary of evidence credibility assessment of 17 unique meta-analyses of observational studies investigating the associations between risk factors and CRC recurrencePopulationOutcomeRisk factorRisk factor prevalenceEffect size (95% CI)Evidence classification**Histopathological risk factor** CRCOverall recurrence in CRCTumor budding802/2773 = 29%5.50 (3.65--8.29)Highly suggestive CRCOverall recurrence in CRCExtranodal extension (ENE)376/877 = 43%2.07 (1.65--2.61)Highly suggestive Rectal cancerLocal recurrence in rectal cancerPerineural invasion (PNI)336/1700 = 20%3.21 (2.33--4.44)Highly suggestive Rectal cancerDistant metastatic recurrence in rectal cancerMRI-detected extramural vascular invasion (mrEMVI)350/1262 = 28%3.91 (2.61--5.86)Highly suggestive CRCLocal recurrence in CRCIntramural vascular invasion (IMVI)137/503 = 27%1.55 (0.11--21.28)No association**Biomarker** CRCOverall recurrence in CRCAbsence of peritoneal free tumor cells in pre-resection524/593 = 88%0.38 (0.16--0.91)Weak CRCOverall recurrence in CRCAbsence of peritoneal free tumor cells in post-resection214/252 = 85%0.07 (0.02--0.21)Weak**Genetic risk factor** CRCOverall recurrence in CRCPTGS2 (also known as COX-2)787/1516 = 52%2.78 (1.76--4.40)Suggestive**Clinical risk factor** CRCLocal recurrence in CRCAnastomotic leakage (AL)3929/39,745 = 10%1.90 (1.48--2.43)Suggestive Rectal cancerLocal recurrence in rectal cancerAnastomotic leakage (AL)1300/13,665 = 10%1.61 (1.25--2.08)Suggestive CRCDistant recurrence in CRCAnastomotic leakage (AL)865/10,392 = 8%1.20 (0.94--1.52)No association Rectal cancerDistant recurrence in rectal cancerAnastomotic leakage (AL)566/5221 = 11%1.06 (0.72--1.58)No association Colon cancerLocal recurrence in colon cancerAnastomotic leakage (AL)91/1990 = 5%2.19 (0.55--8.68)No association**Comorbidity** CRCOverall recurrence in CRCDiabetes429/4979 = 9%1.26 (0.70--2.30)No association**Anthropometric indices** CRCOverall recurrence in CRCUnderweight2752/17,636 = 16%1.13 (1.05--1.21)Weak CRCOverall recurrence in CRCObese6362/21,246 = 30%1.07 (1.02--1.13)Weak CRCOverall recurrence in CRCOverweight13,225/28,109 = 47%1.00 (0.96--1.05)No association*Abbreviation*: *CI* confidence interval, *CRC* colorectal cancer

No risk factor presented convincing evidence (Additional file [1](#MOESM1){ref-type="media"}: Table S10). In addition, four of 11 probed risk factors with *p* \< 0.05 had an effect size suggesting ≥ 3-fold change in the odds of the outcome (Table [2](#Tab2){ref-type="table"}).

Methodological quality and risk of bias assessment {#Sec14}
--------------------------------------------------

We assessed the methodological quality of 10 publications that included 16 meta-analyses of observational studies that statistically represented at least 3-fold changes in the odds of the outcome, using the AMSTAR 2.0 checklist (Additional file [1](#MOESM1){ref-type="media"}: Table S13). All assessed studies had more than one critical flaw \[usually in items 2 (14/16, 88%), 7 (16/16, 100%), and 13 (13/16, 81%)\] and several non-critical flaws \[usually in items 3 (11/16, 69%), 10 (16/16, 100%), and 12 (16/16, 100%)\]. It should be noted that all assessed meta-analyses had critically low quality. Therefore, the credibility of the available evidence should be interpreted with caution.

Sensitivity analysis of redefying the disease outcome groups {#Sec15}
------------------------------------------------------------

We performed a sensitivity analysis to include individual component studies investigating risk factors for *metastasis at presentation* and re-evaluated the credibility of the evidence (Additional file [1](#MOESM1){ref-type="media"}: Table S11). A total of 16 unique meta-analyses including 67 (27%) component studies were retained and investigated. The remaining 185 (73%) studies did not illustrate when metastasis was present (i.e., at diagnosis or after a disease-free period) and therefore could not be included in this sensitivity analysis. Based on the pre-defined criteria, no risk factor presented convincing evidence.

Similarly, a sensitivity analysis was performed to include individual component studies investigating risk factors for *local or distant recurrence* (Additional file [1](#MOESM1){ref-type="media"}: Table S12). A total of 13 unique meta-analyses composed of 81 (58%) component studies (including five meta-analyses investigating distant metastasis after a period of being disease-free) were retained and investigated. The remaining 59 (42%) studies did not separate local or distant recurrence and therefore could not be included in our sensitivity analysis. Furthermore, no risk factor presented convincing evidence (Additional file [1](#MOESM1){ref-type="media"}: Table S12).

Comparative cross-assessment between risk factors evaluated in the umbrella review and risk predictors applied in existing prediction models {#Sec16}
--------------------------------------------------------------------------------------------------------------------------------------------

### Prediction models for CRC metastasis {#Sec17}

Twelve prognostic models have been developed for prediction of CRC metastasis \[[@CR22]--[@CR33]\] (Table [3](#Tab3){ref-type="table"}). The median number of included predictors was four (range 3--9), and 27 unique predictors were included in at least one model. Cancer stage (*N* = 9, 75%) was the most commonly used predictor variable in the 12 prognostic models. Other common predictors included histopathological risk factors such as positive lymph nodes (*N* = 3, 25%), tumor grade or differentiation (*N* = 2, 17%), and tumor histological type (*N* = 3, 25%); biomarker-carcinoembryonic antigen (CEA) (*N* = 3, 25%); age (*N* = 3, 25%); gender (*N* = 2, 17%); and clinical treatment such as surgery, chemotherapy, and radiotherapy (*N* = 3, 25%). Five models (42%) performed internal validation, and four models (33%) were validated in external datasets. Table 3Risk prediction models for CRC metastasisAuthor, yearCountryStudy designPopulationOutcomePrediction time horizonSample size (development/validation)PredictorsModel performance (95%CI)Model presentationInternal validation\*Macias-Garcia, 2015 \[[@CR22]\]SpainDSubmucosal invasive (T1) CRCLymph node metastasisNA97Sessile morphologyAUC 0.90 (0.81--0.99)Risk scoreNATumor differentiationInfiltrative growth patternLymphoid infiltrateTaylor, 1990 \[[@CR23]\]UKDCRCLiver metastasis10 years134SexSensitivity 0.74, specificity 0.62FormulaNAALPDukes BDukes CSegelman, 2014 \[[@CR24]\]SwedenD + IVCRC (I--III)Peritoneal metastasis3 yearscolon 5348/rectal 2696AgeC statistic: colon 0.80, rectal 0.78; calibration plotCalculatorBootstrappingCancer locationpT stagepN stageNo. of lymph nodes examinedPreoperative radiotherapy radicalityType of surgeryAdjuvant chemotherapy\*Huang, 2016 \[[@CR25]\]ChinaD + IVCRCLymph node metastasisNA266/60Radiomics signatureC statistic 0.736 (0.759--0.766); Hosmer--Lemeshow test: *p* = 0.916NomogramRandom splitCEACT-reported LN status\*Hu, 2019 \[[@CR26]\]ChinaD + IVCRC patients with indeterminate pulmonary nodulesLung metastasisNA136/58Chronicity (synchronous nodule or metachronous lesion)AUC 0.929 (0.885--0.974); calibration plotNomogramRandom splitRad-scorepN stage\*Xu, 2019 \[[@CR27]\]ChinaD + IVCRCSynchronous bone metastasisNA41,902/13,967Cancer locationAUC 0.903; sensitivity 0.851; specificity 0.845Risk scoreRandom splitTumor differentiationCancer histological typeCEApN stageBrain metastasisLiver metastasisLung metastasis\*JR, 2019 \[[@CR28]\]KoreaD + EVSubmucosal invasive (T1) CRCLymph node metastasisNA833/722Histologic gradeAUC 0.812 (0.770--0.855); Hosmer--Lemeshow test: *p* = 0.737NomogramNASubmucosal invasionVascular invasionTumor buddingBeumer, 2014 \[[@CR29]\]NetherlandsD + EVCRCDistant metastasis5 years50/43MiR25/miR339AUC 0.80 (0.67--0.93); calibration plotNomogramNAAJCC stageAge at surgerySex\*Wang, 2017 \[[@CR30]\]ChinaDColon cancerPeritoneal metastasisNA1417AgeROC 0.753NomogramNApT stageLesion not traversableInfiltrative growth patternTumor sizeCEAHistopathologic type of mucinous or signet ring cell adenocarcinomaGijn, 2015 \[[@CR31]\]NetherlandsD + IVRectal cancer (tis--III)Metastasis5 years2172Distance from the anal vergeC statistic 0.761 (0.740--0.784); Hosmer--Lemeshow test: *p* = 0.82NomogramCross-validationpT stagepA stagepN stageSurgery typeResidual tumor statusValentini, 2011 \[[@CR32]\]BelgiumD + EVRectal cancer (II--III)Metastasis5 years3458pT stageExternal C statistic 0.73 (0.68--0.77); Wald statistic: *p* = 0.057NomogramRandom splitpN stageSurgery typeAdjuvant chemotherapySun, 2017 \[[@CR33]\]ChinaD + EVRectal cancer (I--III)Distant metastasis5 years425/97CRMC statistic 0.70 (0.64--0.75)/0.71 (0.62--0.81); calibration plotNomogramNAIMA nodesAJCC stageReproduced from He et al. \[[@CR21]\]*Abbreviations*: *D* model development, *D + IV* model development with internal validation, *D + EV* model development with external validation, *AJCC* American Joint Committee on Cancer, *ALP* alkaline phosphatase, *AUC* area under the curve, *CEA* carcinoembryonic antigen, *CRC* colorectal cancer, *CRM* circumferential resection margin, *IMA* inferior mesenteric artery, *NA* non-available, *miRNA* microRNA\*Six recently developed prediction models were additionally included, and data was extracted based on the previous criteria

We conducted a cross-assessment between these predictors and 34 risk factors that were evaluated in our umbrella review. Six of 27 unique predictors (*tumor budding*, *tumor differentiation*, *tumor size*, *vascular invasion*, *submucosal invasion*, and *sex*) were evaluated in the umbrella review (Table [5](#Tab5){ref-type="table"}). The associated ORs for these six risk factors varied from 2.23 to 6.76, and four of them (67%) corresponded to ≥ 3-fold change in the odds of the outcome. Of the remaining 28 risk factors that were not employed in prediction models, ORs varied from 0.45 to 6.78, and 13 (46%) represented ≥ 3-fold change in the odds of the outcome.

In addition, we compared the overlapping outcomes to investigate whether prediction models had included influential risk factors (those presented convincing evidence or with 3-fold change in the odds of the outcome) when they predicted the same outcomes as those evaluated in the umbrella review (Table [6](#Tab6){ref-type="table"}). In total, four overlapping outcomes were found in this cross-assessment (*LNM in pT1 CRC*, *LNM in CRC*, *hepatic metastasis in CRC*, and *distant metastasis in CRC*). For only one outcome (*LNM in pT1 CRC*), two prognostic models \[[@CR22], [@CR28]\] included four risk predictors that were also evaluated in the umbrella review, two of which corresponded to ≥ 3-fold change in the odds of the outcome (*tumor budding*, *tumor differentiation*).

### Prediction models for CRC recurrence {#Sec18}

Twelve prognostic models \[[@CR31], [@CR32], [@CR34]--[@CR43]\] were developed for prediction of CRC recurrence (Table [4](#Tab4){ref-type="table"}). The median number of risk predictors applied in 12 prognostic models was five (range 2--8), and 25 unique predictors were included in at least one model. AJCC (TNM) cancer stage was the predictor variable (*N* = 7, 58%) used in the majority of CRC recurrence risk prediction models. Other common predictor variables included histopathological risk factors such as positive lymph nodes (*N* = 5, 42%), tumor grade or differentiation (*N* = 4, 33%), and tumor size (*N* = 4, 33%); biomarker-CEA (*N* = 4, 33%); cancer location (*N* = 4, 33%); and clinical treatment such as surgery, chemotherapy, radiotherapy, and transfusion (*N* = 5, 42%). Two models (17%) performed internal validation, and 4 models (33%) were validated in external datasets. Table 4Risk prediction models for CRC recurrenceAuthor, yearCountryStudy designPopulationOutcomePrediction time horizonSample size (development/validation)PredictorsModel performance (95%CI)Model presentationInternal validationHoshino, 2016 \[[@CR34]\]JapanDCRC (II)Overall recurrence5 years4167SexC statistic 0.64; calibration plotNomogramNACEATumor locationTumor depthLymphatic invasionVenous invasionNo. of positive lymph nodesPeng, 2010 \[[@CR37]\]ChinaDCRC (II--III)Overall recurrence3 years95AJCC stageAUC 0.75FormulaNAGenetic scoreYing, 2014 \[[@CR38]\]ChinaDCRC (I--III, curative resection)Overall recurrence3 years205Tumor sizeC statistic 0.810/0.890/0.802NomogramNATumor differentiationAJCC stageNLRChemotherapyZakaria, 2007 \[[@CR39]\]JapanDCRC (liver metastasis + hepatectomy)Overall recurrence5 years662HepatoduodenalC statistic 0.61 (0.57--0.64)/0.58 (0.550.61)NomogramNALymph node statusTransfusionsPrimary cancerRegional lymph nodeNo. of metastasisTian, 2017 \[[@CR36]\]ChinaDCRCOverall recurrence3 years556Gene signatureAUC 0.921 (0.869--0.972); calibration plotNomogramNAAJCC stageTumor differentiation\*Kim, 2018 \[[@CR40]\]KoreaD + IVCRC (I)Overall recurrence5 years1538SexC statistic 0.71; calibration plotNomogramNATumor locationpT stageLVITumor size\*Miyoshi, 2016 \[[@CR41]\]JapanD + EVCRC (IV with liver and/or lung metastases)Overall recurrence5 years113Preoperative CEAC statistic 0.631NomogramNATumor locationTumor invasionLymph node metastasisSynchronous metastatic lesions\*Saso, 2018 \[[@CR42]\]JapanD + EVColon cancer (II)Overall recurrence5 years352/213CEA levelC statistic 0.675; external C statistic 0.552NomogramNATumor invasionLymphatic invasionVenous invasionRenfro, 2014 \[[@CR35]\]USAD + EVColon cancer (III)Overall recurrence5 years15,995/1903SexC statistic 0.65; calibration plotNomogramNABMIPST stageLymph node ratioGradeTumor locationTreatmentHida, 2017 \[[@CR43]\]JapanDRectal cancer (II--III)Overall recurrence2 years792Tumor differentiationAUC 0.831FormulaNADepthLymph nodeSurgeryPostoperative complicationTumor heightCEAGijn, 2015 \[[@CR31]\]NetherlandsD + IVRectal cancer (tis-III)Local recurrence6 years1823Distance from the anal vergeC statistic 0.787 (0.761--0.814); Hosmer--Lemeshow test: *p* = 0.68NomogramCross-validationpT stagepN stagepM stageSurgery typeResidual tumor statusRadiotherapyValentini, 2011 \[[@CR32]\]BelgiumD + EVRectal cancer (II--III)Local recurrence5 years3458pT stageExternal C statistic 0.68 (0.59--0.76); Wald statistic: *p* = 0.064NomogramRandom splitcT stagepN stageAgeConcomitant chemotherapyAdjuvant chemotherapyReproduced from He et al. \[[@CR21]\]*Abbreviations*: *D* model development, *D + IV* model development with internal validation, *D + EV* model development with external validation, *AJCC* American Joint Committee on Cancer, *AUC* area under the curve, *BMI *body mass index,  *CEA* carcinoembryonic antigen, *CRC* colorectal cancer, *LVI* lymph vascular invasion, *NA* non-available, *NLR* neutrophil to lymphocyte ratio, *PS*performance status\*Three recently developed prediction models were additionally included, and data was extracted based on the previous criteria

In our cross-evaluation, five of 25 unique predictors (*intramural vascular invasion*, *extramural vascular invasion*, *being underweight*, *being overweight*, and *being obese*) were evaluated in the umbrella review (Table [5](#Tab5){ref-type="table"}). The associated ORs for these five factors varied from 1.00 to 3.91, and only one (20%) (*extramural vascular invasion*) corresponded to ≥ 3-fold change in the odds of the outcome. Of the remaining 12 factors evaluated in the umbrella review, ORs varied from 0.07 to 5.50, and three (25%) represented ≥ 3-fold change in the odds of the outcome. Table 5Cross-assessment of the same risk factors and risk predictorsRisk factor/risk predictorOutcome evaluated in the umbrella reviewRisk factor prevalenceEffect size (95% CI)^**a**^Credibility assessmentOutcome in the risk prediction modelsEffect size (95% CI)^**b**^Model performance**CRC metastasisHistopathological risk factor**  Vascular invasionLymph node metastasis in pT1 CRC330/1731 = 19%2.73 (1.98--3.78)ConvincingLymph node metastasis in pT1 CRC8.45 (4.56--15.66)AUC 0.812 (0.770--0.855); Hosmer--Lemeshow test: *p* = 0.737 (55)Lymph node metastasis in rectal cancer46/168 = 27%5.86 (0.77--44.62)No associationLymph node metastasis in small rectal NETs treated by local excision75/211 = 36%3.63 (0.05--268.57)No association  Tumor buddingLymph node metastasis in pT1 CRC2401/10,128 = 24%6.39 (5.23--7.80)Highly suggestiveLymph node metastasis in pT1 CRC1.70 (1.03--2.80)AUC 0.812 (0.770--0.855); Hosmer--Lemeshow test: *p* = 0.737 (55)Lymph node metastasis in CRC1955/6739 = 29%4.96 (3.97--6.19)Highly suggestive  Tumor differentiationLymph node metastasis in pT1 CRC94/2722 = 4%5.61 (2.90--10.83)SuggestiveLymph node metastasis in pT1 CRC11.77 (0.77--179.83)AUC 0.90 (0.81--0.99) (49)Lymph node metastasis in pT1 CRC patients who underwent additional surgeries after an endoscopic resection122/209 = 58%3.77 (1.12--123.16)No associationSynchronous bone metastasis1.69 (1.22--2.32)AUC 0.903; sensitivity 0.851; specificity 0.845 (54)  Submucosal invasion ≥ 1 mmLymph node metastasis in pT1 CRC2389/2922 = 82%2.95 (1.39--6.27)WeakLymph node metastasis in pT1 CRC2.14 (1.19--3.86)AUC 0.812 (0.770--0.855); Hosmer--Lemeshow test: *p* = 0.737 (55)  Tumor size \> 1 cmLymph node metastasis in rectal cancer203/348 = 58%6.76 (3.25--14.04)Highly suggestivePeritoneal metastasis in colon cancer1.04 (1.00--1.09)ROC 0.753 (57)**Demographic risk factor**  Sex/genderLymph node metastasis in pT1 CRC465/1329 = 35%2.23 (0.78--6.42)No associationLiver metastasis in CRCNASensitivity 0.74; specificity 0.62 (50)Distant metastasis in CRC1.40 (0.46--4.28)AUC 0.80 (0.67--0.93); calibration plot (56)**CRC recurrenceHistopathological risk factor**  Vascular invasion (intramural)Local recurrence in CRC137/503 = 27%1.55 (0.11--21.28)No associationOverall recurrence in stage II CRC1.30 (1.07--1.58)C statistic 0.64; calibration plot (61)  Vascular invasion (extramural)Distant metastatic recurrence in rectal cancer350/1262 = 28%3.91 (2.61--5.86)Highly suggestiveOverall recurrence in stage II colon cancer2.48 (1.22--5.57)C statistic 0.675; external C statistic 0.552 (68)**Anthropometric indices**  BMI (underweight)Overall recurrence in CRC2752/17,636 = 16%1.13 (1.05--1.21)WeakOverall recurrence in stage III colon cancerNAC statistic 0.65; calibration plot (69)  BMI (overweight)Overall recurrence in CRC13,225/28,109 = 47%1.00 (0.96--1.05)No association  BMI (obese)Overall recurrence in CRC6362/21,246 = 30%1.07 (1.02--1.13)Weak*Abbreviations*: *AUC* area under the curve, *BMI* body mass index, *CI* confidence interval, *CRC* colorectal cancer, *NA* non-available^a^Effect size (95% CI), effect size from the umbrella review^b^Effect size (95% CI), effect size from the risk prediction models

In relation to overlapping outcomes, only one outcome (*overall recurrence in CRC*) was identified (Table [6](#Tab6){ref-type="table"}). However, the prognostic model \[[@CR36]\] included risk predictors that were not evaluated in the umbrella review (*cancer stage*, *tumor differentiation*, and *gene signature*). Meanwhile, within the evaluated nine risk factors for overall recurrence in CRC that were not employed as predictors in this model, only two influential risk factors (*tumor budding*, *absence of peritoneal free tumor cells in post-resection*) had ≥ 3-fold change in the odds of the outcome. Table 6Cross-assessment of the same outcomes with their corresponding risk factors and predictorsOverlapping outcomesRisk factorRisk factor prevalenceEffect size (95% CI)^**a**^Credibility assessmentRisk predictorEffect size (95% CI)^**b**^Model performance**CRC metastasis** Lymph node metastasis in pT1 CRCVascular invasion330/1731 = 19%2.73 (1.98--3.78)ConvincingVascular invasion8.45 (4.56--15.66)AUC 0.812 (0.770--0.855); Hosmer--Lemeshow test: *p* = 0.737 (55)Submucosal invasion ≥ 1 mm2389/2922 = 82%2.95 (1.39--6.27)WeakSubmucosal invasion ≥ 1 mm2.14 (1.19--3.86)Tumor budding2401/10,128 = 24%6.39 (5.23--7.80)Highly suggestiveTumor budding1.70 (1.03--2.80)Histologic grade7.89 (2.89--21.52)Tumor differentiation94/2722 = 4%5.61 (2.90--10.83)SuggestiveTumor differentiation11.77 (0.77--179.83)AUC 0.90 (0.81--0.99) (49)Lymphatic invasion906/3347 = 27%6.78 (5.29--8.69)Highly suggestiveInfiltrative growth pattern31.91 (2.37--428.36)Lymphovascular invasion340/1695 = 20%4.81 (3.14--7.36)SuggestiveLymphoid infiltrate28.75 (2.13--388.37)Gender465/1329 = 35%2.23 (0.78--6.42)No associationSessile morphology4.88 (0.81--29.3) Lymph node metastasis in CRCTumor budding1955/6739 = 29%4.96 (3.97--6.19)Highly suggestiveCT-reported lymph node status1.69 (1.05--2.75)C statistic 0.736 (0.759--0.766); Hosmer--Lemeshow test: *p* = 0.916 (52)Downregulated E-cadherin expression829/1573 = 53%0.49 (0.34--0.72)Highly suggestiveRadiomics signature5.48 (3.03--9.91)Low MUC2 expression level613/1335 = 46%1.42 (1.19--1.69)SuggestiveCEA1.71 (1.04--2.83)Circulating tumor cells797/1802 = 44%1.62 (1.17--2.23)Weakp16 protein expression482/800 = 60%0.50 (0.30--0.84)WeakCD147 expression603/815 = 74%1.41 (0.39--5.01)No associationCD133 expression550/1629 = 34%1.15 (0.82--1.62)No associationHER-2 immunohistochemical expression440/1289 = 34%1.90 (0.90--4.02)No associationBRAF mutation736/1142 = 64%0.75 (0.49--1.14)No associationRASSF1A promoter methylation100/184 = 54%1.61 (0.16--16.16)No association Hepatic metastasis in CRCCirculating tumor cells103/310 = 33%6.38 (2.67--15.26)SuggestiveDuke B/CNASensitivity 0.74, specificity 0.62 (50)ALPNASex/genderNA Distant metastasis in CRCDownregulated E-cadherin expression509/1027 = 50%0.45 (0.23--0.91)WeakAJCC stage1.27 (0.25--6.38)AUC 0.80 (0.67--0.93); calibration plot (56)Cyclin D1 overexpression952/1515 = 63%0.60 (0.36--0.99)WeakMiR25/MiR3392.92 (0.98--8.64)β-catenin overexpression in the nucleus283/531 = 53%0.48 (0.29--0.79)WeakAge at surgery1.10 (0.20--6.03)CD147 expression405/538 = 75%2.32 (1.34E−06 to 4.03E+06)No associationSex/gender1.40 (0.46--4.28)CD133 expression300/1064 = 28%1.54 (0.39--6.09)No associationRASSF1A promoter methylation153/417 = 37%2.57 (0.64--10.24)No association**CRC recurrence** Overall recurrence in CRCTumor budding802/2773 = 29%5.50 (3.65--8.29)Highly suggestiveAJCC stageNAAUC 0.921 (0.869--0.972); calibration plot (65)Extranodal extension (ENE)376/877 = 43%2.07 (1.65--2.61)Highly suggestiveTumor differentiationNAPTGS2 (COX-2)787/1516 = 52%2.78 (1.76--4.40)SuggestiveGene signatureNAAbsence of peritoneal free tumor cells in pre-resection524/593 = 88%0.38 (0.16--0.91)WeakAbsence of peritoneal free tumor cells in post-resection214/252 = 85%0.07 (0.02--0.21)WeakUnderweight2752/17,636 = 16%1.13 (1.05--1.21)WeakObese6362/21,246 = 30%1.07 (1.02--1.13)WeakOverweight13,225/28,109 = 47%1.00 (0.96--1.05)No associationDiabetes429/4979 = 9%1.26 (0.70--2.30)No association*Abbreviations*: *ALP* alkaline phosphatase, *AUC* area under the curve, *BMI* body mass index, *CEA* carcinoembryonic antigen, *CI* confidence interval, *CRC* colorectal cancer, *NA* non-available, *miRNA* microRNA^a^Effect size (95% CI), effect size from the umbrella review^b^Effect size (95% CI), effect size from the risk prediction models

Discussion {#Sec19}
==========

We initially synthesized and evaluated the evidence of risk factors for CRC metastasis and recurrence. Our study comprised 51 unique meta-analyses of observational studies investigating 34 risk factors for CRC metastasis and 17 risk factors for recurrence. We also conducted a sensitivity analysis of 29 unique meta-analyses of risk factors for CRC metastasis at presentation (*n* = 16), CRC local recurrence (*n* = 5), and CRC distant recurrence (*n* = 8) using a standardized categorization of the component studies. Furthermore, we updated synthesis of risk prediction models for CRC metastasis (*n* = 12) and recurrence (*n* = 12) and then conducted a cross-assessment of individual risk factors evaluated in the umbrella review and risk predictors included in existing prediction models, which allowed us to examine to what extent predictive models include the most influential factors.

Main findings and interpretation of the umbrella review {#Sec20}
-------------------------------------------------------

### Meta-analyses for CRC metastasis {#Sec21}

According to our pre-defined criteria for assessing the credibility of the evidence, only one risk factor was classified as convincing (*vascular invasion for LNM in pT1 CRC*), reflecting strong statistical significance and no hints of bias. Many studies have demonstrated that the invasion of blood vessels leading to tumor cell dissemination and metastasis is a strong risk factor for disease prognosis, which is in line with our umbrella review \[[@CR44], [@CR45]\]. Based on our findings, a large proportion of studies (17/25, 68%) investigated lymphatic and vascular invasion as separate risk factors, while 32% of studies categorized them jointly as lymphovascular invasion. It has been shown though that the predictive ability of lymphovascular invasion is lower than that of vascular invasion \[[@CR46]\].

Twelve (35%) of 34 probed risk factors for metastasis had an effect size suggesting ≥ 3-fold change in the odds of the outcome with *p* \< 0.05. Four of these risk factors (*lymphatic invasion for LNM in pT1 CRC*; *tumor budding for LNM in pT1 CRC*; *tumor budding for LNM in all stage CRC*; *tumor size \> 1 cm for LNM in rectal cancer*) were classified as highly suggestive. As discussed above, *lymphatic invasion* could be an indicator of tumor cells metastasizing to lymph nodes. This finding agrees with three recently published studies manifesting that lymphatic invasion is causally associated with the risk of LNM in CRC \[[@CR47]--[@CR49]\]. *Tumor budding* is recognized as a negative prognostic risk factor for LNM in CRC, and our findings are concordant with previous studies \[[@CR50]--[@CR52]\]. Individual component studies vary in their definitions of tumor budding (e.g., how many cancer cells comprise a tumor bud, and how many buds signify tumor budding) and vary in the pathologic staining methods to detect tumor budding (e.g., hematoxylin and eosin \[H&E\], immunohistochemistry \[IHC\]). Furthermore, a systematic review summarized pathologic methods to detect tumor budding and revealed that all studies even when utilizing different methods showed that tumor budding increases the risk of CRC metastasis \[[@CR53]\]. Notably, substantial between-study heterogeneity (*I*^2^ \> 50%) was found in the meta-analysis investigating tumor budding for LNM in all CRC stages, indicating that this association needs to be interpreted with caution. The observed heterogeneity may be influenced by the inclusion of different tumor stages. Finally, *tumor size \> 1 cm* is associated with an increased risk of LNM in rectal cancer. This largely agrees with the European Society for Medical Oncology (ESMO) clinical practice guideline manifesting that a rectal lesion less than 1 cm has a lower risk of metastasis, and therefore, local excision (TEM) is suggested \[[@CR54]\].

### Meta-analyses for CRC recurrence {#Sec22}

In regard to 17 probed risk factors for CRC recurrence, four (24%) had an effect size suggesting ≥ 3-fold change in the odds of the outcome with *p* \< 0.05. None of them presented convincing evidence. Three (*tumor budding for overall recurrence in CRC*; *perineural invasion \[PNI\] for local recurrence in rectal cancer*; *MRI-detected extramural vascular invasion \[mrEMVI\] for distant metastatic recurrence in rectal cancer*) were classified as highly suggestive. Our findings suggest that *tumor budding* is a common highly suggestive risk factor for both CRC LNM and overall recurrence. However, there is a need for standardization of the histopathological definition of tumor budding \[[@CR46]\]. Another histopathological risk factor, *PNI*, which is a common pathological feature in rectal cancer, strongly signifies local recurrence. Compared to colon cancer, PNI occurs more frequently in rectal cancer, since there is a cluster of intensive neural plexuses surrounding the pelvis in the rectum \[[@CR55]\]. The National Comprehensive Cancer Network (NCCN) guidelines also suggest that patients with PNI positive are at higher risk of local recurrence \[[@CR56]\]. However, there is no consensus in the definition of PNI positive, with two of the most frequently used definitions being SS-PNI (when tumor cells surround at least 33% of the nerve) and TS-PNI (when tumor cells surround any of the three layers of the nerve) \[[@CR57]--[@CR60]\]. Finally, we found that *mrEMVI* increases the risk of distant metastatic recurrence. EMVI is the venous invasion beyond the muscularis propria, which has long been recognized as a risk factor for distant recurrence \[[@CR61]--[@CR63]\]. The 5-point MRI-detected EMVI scoring system is precise for detecting this invasion, and it is recommended as a post-operation follow-up strategy in clinical settings \[[@CR64]\]. In addition, a recently published meta-analysis is also in line with our findings, reporting that around 90% of patients with liver metastases are mrEMVI positive \[[@CR65]\].

### Sensitivity analysis {#Sec23}

In our effort for a consistent definition of metastasis and recurrence, we re-categorized all the component studies to three distinct disease outcomes: metastasis at presentation, local recurrence, and distant recurrence. This could generate insight into metastasis and recurrence patterns and provide investigators and clinicians with a more comprehensive summary of risk factors for these CRC prognostic outcomes with clinical significance \[[@CR66]\]. Our sensitivity analyses reported a dearth of convincing evidence. However, a total of 244 (62%) individual component studies were excluded from our sensitivity analyses due to missing information in relation to outcome definition.

Cross-assessment between risk factors evaluated in the umbrella review and risk predictors applied in existing prediction models {#Sec24}
--------------------------------------------------------------------------------------------------------------------------------

We identified 24 CRC prognostic models for metastasis (*n* = 12) and recurrence (*n* = 12). The majority of risk prediction models applied an average of four to five predictor variables. The most commonly used predictors were clinic-histopathological (cancer stage, lymph node status) and demographic (gender, age) parameters. Seven models were validated internally and eight in external datasets, but none of the identified models conducted any impact studies. As for model presentation, the majority of models were nomograms (graphical prediction models), and the remaining models were presented as formulae, risk scores, and calculators.

In our cross-assessment, we investigated whether the identified prediction models had employed influential risk factors (those presented convincing evidence or with 3-fold change in the odds of the outcome) when they predicted the same outcomes as those that were evaluated in the umbrella review. Across 12 CRC metastasis risk prediction models, five models \[[@CR22], [@CR23], [@CR25], [@CR28], [@CR29]\] were on the same outcomes (*LNM in pT1 CRC*, *LNM in CRC*, *hepatic metastasis in CRC*, and *distant metastasis in CRC*), with only two \[[@CR22], [@CR28]\] of these models (*on LNM in pT1 CRC*) including predictors also evaluated in the umbrella review. However, the models' calibration was poorly reported, which made it difficult to assess the models' predictive accuracy. Furthermore, one model \[[@CR28]\] was externally validated to ensure the model's applicability and generalizability, while the remaining one \[[@CR22]\] did not undergo adequate validation to address its potential overfitting. In addition, the remaining three models \[[@CR23], [@CR25], [@CR29]\] predicting LNM and DM in CRC applied other risk predictors such as cancer stage, CEA, and alkaline phosphatase (ALP) that were not evaluated in the umbrella review. We suggest that risk factors with strong associations with CRC prognosis, such as circulating tumor cells and microsatellite instability, should be employed following evidence-based methods.

Across the 12 CRC recurrence risk prediction models, only one model \[[@CR36]\] was on an outcome that was also evaluated in the umbrella review (*overall recurrence in CRC*). Unfortunately, we did not find overlapping risk factors/predictors. We recommend tumor budding and absence of peritoneal free tumor cells in post-resection (≥ 3-fold change in the odds of the outcome) to be considered as predictors.

Clinical implications and future research {#Sec25}
-----------------------------------------

Identifying and evaluating risk factors with substantial predictive value is of great clinical importance. Major clinical decisions are made taking into account expectations and formal or informal predictions about major outcomes. Accurate and valid risk prediction could assist with clinical decision-making in relation to the extent and mode of surgery and therapy. Ideally, adjuvant treatment would be targeted with precision to those most likely to benefit; those most at risk of CRC metastasis/recurrence may also have a higher absolute probability of benefit. The majority of patients do not benefit from additional therapy aimed at preventing locoregional or distant relapse before or after surgical resection, and yet they may be exposed to the attendant morbidity, cost, and false expectation of such therapy. Therefore, accurate and valid risk prediction which could impact clinical decision-making is crucial. In summary, this umbrella review provides an evidence classification that could help clinicians to judge the relative priority of risk factors/predictors' impact on CRC prognosis and make clinical decisions based on more accurate and valid risk prediction.

Our findings suggest that efforts to address the limitations of the available evidence could be beneficial. Large-scale prospective studies are needed to generate evidence less prone to bias and allowing better predictive model building and validation. Standardizing the outcome definitions of CRC metastasis and recurrence could improve reporting of outcomes that have direct clinical relevance. Future risk prediction model research is encouraged to apply rigorous model construction processes and to integrate the most influential risk factors based on evidence-based methods.

Strengths and limitations {#Sec26}
-------------------------

The main strength of this study is that it provides a rigorous critical assessment of the published epidemiological evidence on risk factors of CRC metastasis and recurrence, based on pre-defined criteria in a transparent and systematic way \[[@CR17], [@CR18]\]. In addition, we updated the synthesis of CRC prognostic prediction models, and to our best knowledge, this is the first cross-assessment between individual risk factors and risk predictors applied in existing prediction models, to investigate whether influential risk factors are employed as predictors. Our findings provide a comprehensive evaluation of available evidence that can inform future research on risk factors for CRC prognostic outcomes and risk prediction models.

However, the following potential limitations should be considered. First, umbrella review comprises a synthesis of evidence from existing systematic reviews and meta-analyses \[[@CR67]\]. Therefore, risk factors and risk predictors that were not systematically reviewed in the pre-existing literature are not included in this umbrella review. These may include some factors that are commonly used in predictive models, and it highlights the need to perform systematic reviews of the evidence for factors that might be routinely or frequently measured. Second, meta-analyses have common defects such as limited coverage of the literature search and low quality of the included studies \[[@CR68], [@CR69]\]. Third, this study only collected and evaluated evidence from systematic reviews and meta-analyses of observational studies published in peer-reviewed journals. This could limit the breadth of our results if research in gray literature, conference abstracts, and comments investigated risk factors that were not included in this umbrella review. Furthermore, 77% of meta-analyses included only retrospective studies.

Moreover, this study did not evaluate the quality of all individual component studies included in each meta-analysis because it is beyond the scope of an umbrella review. Instead, we performed a credibility evaluation and risk of bias assessment for meta-analyses that represented at least 3-fold changes in the odds of the outcome. Criteria for assessing the evidence from meta-analyses of observational studies applied in our umbrella review were based on pre-defined metrics whose limitations have been summarized \[[@CR70]--[@CR72]\]. For the outcomes that we studied, one is probably interested usually on whether the considered risk factors confer substantial predictive value, rather than whether they are causally related to the outcomes. We pre-specified a threshold for the magnitude of what might be a relatively large effect size (3-fold change in odds), but this is not absolute. The predictive value may depend also on how frequently a given factor is in the evaluated population. However, with one exception, all the factors evaluated concurrently in both risk factor meta-analyses and in predictive models were pretty common, with prevalence ranging from 16 to 82%.

We should also acknowledge that although we performed a sensitivity analysis to classify CRC metastasis at presentation, local or distant recurrence, a large proportion (62%) of individual component studies did not present enough information, such as the timing of metastasis in relation to initial diagnosis (i.e., synchronous or metachronous) and local or distant recurrence separately from overall recurrence. Finally, we did not evaluate risk factors relevant to clinical interventions such as surgery type, chemotherapy, radiotherapy, and transfusion. We also could not perform a complete comparison between risk factors evaluated in the umbrella review and risk predictors applied in existing prediction models because only 11 overlapping risk factors/predictors were identified.

Conclusions {#Sec27}
===========

In this umbrella review, we synthesized and evaluated risk factors and risk prediction models of CRC metastasis and recurrence. A total of 51 unique risk factors were investigated, convincing evidence exists only for the association between vascular invasion and LNM, and even that is restricted to pT1 tumors. Furthermore, we also conducted a cross-assessment to evaluate individual risk factors and risk prediction models. Our findings emphasize the need for a more rigorous and systematic model construction process to integrate influential risk factors following evidence-based methods.
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AMSTAR 2.0

:   Assessment of Multiple Systematic Reviews 2.0

ALP

:   Alkaline phosphatase

CEA

:   Carcinoembryonic antigen

CI

:   Confidence interval

CRC

:   Colorectal cancer

DL

:   DerSimonian and Laird

EMR

:   Endoscopic resection

ESMO

:   European Society for Medical Oncology

H&E

:   Hematoxylin and eosin

HKSJ

:   Hartung-Knapp-Sidik-Jonkman

HR

:   Hazard ratio

IHC

:   Immunohistochemistry

LNM

:   Lymph node metastasis

mrEMVI

:   MRI-detected extramural vascular invasion

NCCN

:   National Comprehensive Cancer Network

OR

:   Odds ratio

PNI

:   Perineural invasion

PRISMA-P

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols

RR

:   Risk ratio

TEM

:   Trans-anal microscopic surgery
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